The PD-1/PD-L1 pathway regulates T cell activation during inflammatory processes, while CTLA-4 is a protein receptor on T cell surface, inhibiting T cell activity during the priming phase; miR-424 may inhibit the PD1/PD-L1 and CD80/CTLA-4 activity, inducing tumor suppression [46]. The gene discussed is CD80; the disease is neoplasm.